TP53 and cancer: Networks with a principal alteration of TP53 were identified in 7 out of 73 patients suggesting one of 12 drugs (gemcitabine, epirubicin, doxorubicin, paclitaxel or capecitabine, docetaxel, thiotepa, abemaciclib, tamoxifen, olaparib, cyclophosphamide, or alpelisib) as personalized cancer therapy regimen.